|
The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcSé-crizotinib program. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Léo Pharma; Pfizer; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; HalioDx; Ipsen; MSD Oncology; Pierre Fabre |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Hospira; Ipsen; Ipsen; Novartis; Roche |
|
|
No Relationships to Disclose |
|
Christelle De La Fouchardiere |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Roche; Shire |
|
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Merck Serono; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis |
Travel, Accommodations, Expenses - Ipsen; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
Carlos Alberto Gomez-Roca |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Celine Mahier - Ait Oukhatar |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb |